Basilea Pharmaceutica AG (SWX:BSLN)
Switzerland · Delayed Price · Currency is CHF 64.60
-1.00 (-1.52%)
Aug 21, 2026, 5:31 PM CET
Basilea Pharmaceutica AG Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Basilea Pharmaceutica AG stock has a consensus rating of "Buy" and an average price target of CHF 88.50. The average 1-year stock price forecast is 37.00% higher than the current stock price, while the lowest is CHF 59.40 (-8.05%) and the highest is CHF 126.10 (+95.20%).
Price Target: CHF 88.50 (+37.00%)
Analyst Consensus: Buy
Price Target
Chart* Price targets were last updated on Apr 13, 2026.
Analyst Ratings
The average analyst rating for Basilea Pharmaceutica AG stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Kepler Capital | Kepler Capital | Buy Maintains CHF 69.00 → CHF 70.00 | Buy | Maintains | CHF 69.00 → CHF 70.00 | +8.36% | Apr 13, 2026 |
Financial Forecast
Revenue This Year
260.64M
from 232.38M
Increased by 12.16%
Revenue Next Year
270.52M
from 260.64M
Increased by 3.79%
EPS This Year
3.40
from 3.14
Increased by 8.28%
EPS Next Year
4.29
from 3.40
Increased by 26.09%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CHF.